Clinical Trial Update: Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Pemigatinib in relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell lymphoma and marginal zone lymphoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

Sponsor: University of Utah | Conditions: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING